Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes

NARecruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Monogenic Diabetes
Interventions
DIAGNOSTIC_TEST

Genetic Screening for Monogenic Diabetes

"This intervention involves genetic testing for monogenic diabetes (MDM) in recruited participants. The testing includes either a panel test specifically targeting genes associated with monogenic diabetes or whole exome sequencing (WES) to comprehensively identify genetic variants linked to MDM.~Precise diagnosis and treatmen:~1. The clinical trial of individualized treatment was carried out for the individuals with diabetes with HNF1A mutation.~2. The research team will closely follow up individuals with GCK mutation diabetes after suspending the current hypoglycemic drugs, and evaluate their clinical glucose metabolism related indicators.~3. Observe the dosage of sulfonylurea drugs used in individuals with different disease course and pancreatic function, and observe the impact of disease course and pancreatic function on the success rate of oral drug replacement."

Trial Locations (1)

300052

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER